ProHance (Gadoteridol)
Gadolinium-Based MRI Contrast Agent
Quick Facts About ProHance
Key Takeaways
- ProHance (gadoteridol) is a macrocyclic gadolinium-based MRI contrast agent used to enhance imaging of the brain, spinal cord, and whole body.
- Its macrocyclic chelate structure offers greater stability than linear agents, resulting in a lower risk of gadolinium retention and nephrogenic systemic fibrosis (NSF).
- The standard dose is 0.2 mL/kg body weight administered intravenously; it should not be used in patients with severe renal impairment unless absolutely necessary.
- The most common side effect is nausea; serious reactions such as anaphylaxis and NSF are rare but require immediate medical attention.
- ProHance should only be used during pregnancy if the diagnostic benefit clearly outweighs the risk; breastfeeding mothers should consider pausing for 24 hours after administration.
What Is ProHance and What Is It Used For?
ProHance contains the active substance gadoteridol, a non-ionic macrocyclic gadolinium chelate. When injected into a vein, gadoteridol distributes throughout the bloodstream and into tissues, where it alters the magnetic relaxation times of nearby water protons. This effect produces enhanced signal intensity (brightening) on T1-weighted MRI sequences, allowing radiologists to more clearly differentiate between normal and abnormal tissues.
The primary clinical indications for ProHance include contrast-enhanced MRI of the central nervous system (CNS), specifically the brain and spinal cord, where it helps detect lesions such as tumors, infections, demyelinating diseases, and vascular malformations. By crossing disrupted areas of the blood-brain barrier, ProHance accumulates in abnormal tissue and makes pathology more visible against the background of normal brain or spinal cord tissue.
In adults, ProHance is also approved for whole-body MRI, enabling enhanced imaging of structures throughout the body. This can be particularly useful in oncological staging, detecting metastatic disease, evaluating musculoskeletal abnormalities, and assessing vascular conditions. The broad distribution profile of gadoteridol makes it a versatile imaging tool for a wide range of diagnostic scenarios.
ProHance belongs to a class of gadolinium-based contrast agents known as macrocyclic agents. The macrocyclic structure refers to the cage-like molecular architecture that encapsulates the gadolinium ion, providing significantly greater thermodynamic and kinetic stability compared to linear gadolinium chelates. This structural advantage means that gadoteridol is less likely to release free gadolinium ions in the body, which is an important safety consideration. International regulatory bodies, including the European Medicines Agency (EMA), have recognized the superior stability profile of macrocyclic agents and have restricted the use of certain linear agents due to concerns about gadolinium deposition in the brain.
It is important to understand that ProHance is only for diagnostic purposes. It does not treat any medical condition; rather, it serves as a tool that helps physicians make more accurate diagnoses by improving the contrast and clarity of MRI images. The decision to use ProHance is made by the radiologist or referring physician based on the clinical question being addressed and the expected diagnostic benefit.
What Should You Know Before Taking ProHance?
While ProHance is generally well tolerated, there are important medical considerations that must be evaluated before administration. Your healthcare provider will review your medical history and may perform laboratory tests to ensure that ProHance is safe for you. Being fully transparent about your health status is critical for minimizing the risk of adverse reactions.
Contraindications
Do not use ProHance if you are allergic (hypersensitive) to gadoteridol or any of the other ingredients in the formulation. Known hypersensitivity to gadoteridol or to any excipient is an absolute contraindication. If you have experienced a previous allergic reaction to any gadolinium-based contrast agent, inform your doctor immediately, as cross-reactivity between different GBCAs is possible, though not universal.
Warnings and Precautions
Inform your healthcare provider before receiving ProHance if any of the following conditions apply to you:
- Kidney impairment: If your kidneys do not function normally, your doctor may order a blood test (estimated glomerular filtration rate, eGFR) to assess renal function before deciding whether to use ProHance. This is particularly important because impaired kidney function slows the elimination of gadolinium from the body, increasing the risk of nephrogenic systemic fibrosis (NSF).
- Recent or planned liver transplant: Patients in the perioperative phase of liver transplantation are at higher risk of acute kidney injury, which in turn increases the risk of NSF following gadolinium exposure.
- History of allergies: Patients with a history of allergic reactions, asthma, or other hypersensitivity disorders may be at increased risk of allergic reactions to contrast agents. Premedication with corticosteroids or antihistamines may be considered in such cases.
- Epilepsy or brain injury: If you have a history of seizure disorders or brain injury, inform your doctor, as gadolinium-based agents may theoretically lower the seizure threshold in susceptible individuals.
ProHance is not recommended for patients with severe kidney impairment (GFR <30 mL/min/1.73 m²) or patients who have recently had or are about to have a liver transplant, due to the risk of NSF. If use is necessary in such patients, only one dose should be given per examination, and at least 7 days should elapse before a repeat injection.
Neonates and Infants
Because neonates (up to 4 weeks of age) and infants (up to 1 year of age) have immature kidney function, ProHance should only be administered to these patients after careful consideration by the physician. The dose should not exceed 0.1 mmol/kg body weight, and no more than one dose should be given per examination. At least 7 days should pass between repeat injections, as the reduced renal clearance in very young patients increases the duration of gadolinium exposure.
Pregnancy and Breastfeeding
Pregnancy: Gadolinium can cross the placenta, and its effects on the developing fetus are not fully established. ProHance should not be used during pregnancy unless the diagnostic information is absolutely necessary and cannot be obtained through non-contrast MRI or other imaging methods. If you are pregnant, suspect you may be pregnant, or are planning a pregnancy, inform your doctor before the procedure. International guidelines from the American College of Radiology (ACR) and the European Society of Urogenital Radiology (ESUR) recommend avoiding gadolinium administration during pregnancy whenever possible.
Breastfeeding: Only a very small amount of gadoteridol is excreted in breast milk, and even less is absorbed from the infant's gastrointestinal tract. Nevertheless, as a precautionary measure, your doctor may discuss whether you should continue breastfeeding or temporarily suspend breastfeeding for a period of 24 hours after receiving ProHance. Current evidence from the ACR and ESUR suggests that it is safe to continue breastfeeding after gadolinium administration, but the decision should be made jointly by the mother and physician.
Driving and Operating Machinery
ProHance has no or negligible effect on the ability to drive and use machines. However, if you feel drowsy, dizzy, or unwell after the examination (for example, experiencing nausea), you should not drive or operate machinery until symptoms have resolved. You are responsible for assessing whether you are fit to perform these activities.
ProHance contains less than 1 mmol (23 mg) of sodium per dose, making it essentially sodium-free. This is relevant for patients on sodium-restricted diets.
How Does ProHance Interact with Other Drugs?
One of the advantages of ProHance as a diagnostic agent is its relatively simple pharmacokinetic profile. Gadoteridol does not undergo metabolic transformation in the body and is eliminated almost entirely by renal excretion in its unchanged form. This means there is no involvement of cytochrome P450 enzymes or other hepatic drug-metabolizing pathways, significantly reducing the likelihood of pharmacokinetic drug-drug interactions.
No formal interaction studies have been performed with gadoteridol, and to date, no clinically relevant interactions have been identified. However, as with any medication, it is good practice to inform your healthcare provider about all medications you are currently taking, have recently taken, or might take. This includes prescription drugs, over-the-counter medications, vitamins, and herbal supplements.
While specific interactions are not established, certain clinical considerations apply. Medications that affect kidney function, such as non-steroidal anti-inflammatory drugs (NSAIDs), aminoglycoside antibiotics, ACE inhibitors, and certain diuretics, may theoretically influence the renal clearance of gadoteridol. In patients with pre-existing renal impairment, any additional renal insult from concurrent nephrotoxic drugs could slow the elimination of gadolinium and increase the duration of systemic exposure.
Additionally, patients taking beta-blockers may have a reduced response to epinephrine (adrenaline) in the event of an anaphylactic reaction to ProHance. This is an important consideration for emergency preparedness rather than a direct pharmacokinetic interaction. Radiologists and MRI staff should be aware of this when managing patients who receive gadolinium-based contrast agents.
| Drug Class | Consideration | Clinical Relevance |
|---|---|---|
| NSAIDs | May reduce renal function | Monitor kidney function in at-risk patients |
| Aminoglycosides | Nephrotoxic potential | Assess renal function before gadolinium |
| Beta-blockers | May blunt response to epinephrine | Important for anaphylaxis management |
| Metformin | Renal clearance considerations | Follow local contrast media protocols |
| ACE inhibitors / ARBs | May affect renal hemodynamics | Assess eGFR in patients with risk factors |
It is worth noting that gadolinium-based contrast agents should not be mixed with other medications in the same syringe or infusion line. ProHance should be administered as a separate intravenous injection. No incompatibility testing with other pharmaceutical products has been performed, and mixing could potentially compromise the stability of the chelate complex or cause precipitation.
What Is the Correct Dosage of ProHance?
ProHance is always administered by trained healthcare professionals in a clinical setting. You will not need to prepare the injection yourself. The dose is calculated based on your body weight to ensure optimal contrast enhancement while minimizing the total gadolinium exposure. The injection is given intravenously (into a vein), typically in the arm, immediately before or during the MRI scan.
Adults
Brain and Spinal Cord MRI
The recommended dose is 0.2 mL/kg body weight (equivalent to 0.1 mmol/kg). In certain clinical situations where additional diagnostic information is required, the dose may be increased to 0.6 mL/kg body weight (0.3 mmol/kg). The decision to use a higher dose is made by the radiologist based on the clinical indication and initial imaging findings.
Whole-Body MRI
The recommended dose for whole-body imaging is 0.2 mL/kg body weight (0.1 mmol/kg). This dose provides adequate contrast enhancement for evaluating structures throughout the body, including the liver, kidneys, musculoskeletal system, and vascular structures.
Children (from Full-Term Neonates)
Brain and Spinal Cord MRI in Pediatric Patients
The recommended dose for children is 0.2 mL/kg body weight (0.1 mmol/kg). For neonates (up to 4 weeks) and infants (up to 1 year), the dose should not exceed 0.1 mmol/kg body weight due to immature renal function. Only one dose should be given per examination, with at least 7 days between repeat administrations.
Elderly Patients
No dose adjustment is necessary for patients aged 65 years and older. However, because renal function may decline with age, a blood test to measure kidney function (eGFR) may be performed before ProHance administration to ensure safe use. If renal impairment is identified, the physician will assess the benefit-risk ratio before proceeding.
Patients with Kidney Problems
ProHance is not recommended for patients with severe kidney impairment (GFR <30 mL/min/1.73 m²) or patients in the perioperative phase of liver transplantation due to the risk of nephrogenic systemic fibrosis (NSF). If use is deemed absolutely necessary after careful risk-benefit assessment, the dose should not exceed 0.1 mmol/kg body weight. Only one dose should be administered per examination, and at least 7 days must elapse before any repeat injection.
| Patient Group | Indication | Recommended Dose | Maximum Dose |
|---|---|---|---|
| Adults | Brain & spinal cord MRI | 0.2 mL/kg | 0.6 mL/kg |
| Adults | Whole-body MRI | 0.2 mL/kg | 0.2 mL/kg |
| Children (full-term neonates+) | Brain & spinal cord MRI | 0.2 mL/kg | 0.2 mL/kg |
| Neonates/Infants (<1 year) | CNS MRI (if necessary) | 0.1 mmol/kg | 0.1 mmol/kg; min. 7 days between doses |
| Severe renal impairment | Only if essential | 0.1 mmol/kg | Single dose; min. 7 days between doses |
Overdose
In the event of an accidental overdose, the patient should be monitored clinically and supportive care provided as needed. Because gadoteridol is eliminated renally, patients with normal kidney function will clear the excess dose through urine. In patients undergoing hemodialysis, the procedure can help remove gadoteridol from the body more rapidly. If you suspect an overdose, contact your healthcare provider or local poison control center immediately for risk assessment and advice.
How ProHance Is Administered
ProHance is always given by a healthcare professional in a radiology department or imaging center. The injection is administered intravenously, typically into a vein in your arm. In many facilities, a power injector is used to deliver the contrast agent at a controlled, consistent rate. After the gadolinium injection, a flush of normal saline solution is often administered to ensure complete delivery of the contrast dose. You will be positioned in the MRI scanner, and images will be acquired at specific time intervals after injection to capture optimal contrast enhancement.
What Are the Side Effects of ProHance?
Like all medicines, ProHance can cause side effects, although not everybody gets them. Most side effects associated with gadolinium-based contrast agents are mild and self-limiting, resolving within minutes to hours after administration. However, it is important to be aware of both common and rare side effects so that you can recognize them and seek medical attention if needed.
The frequency categories used below follow international convention: common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people), rare (may affect up to 1 in 1,000 people), and not known (frequency cannot be estimated from available data).
Common
- Nausea
Uncommon
- Headache
- Altered sensation (paresthesia)
- Drowsiness
- Taste changes (dysgeusia)
- Low blood pressure (hypotension)
- Hot flushes
- Dry mouth
- Vomiting
- Itching (pruritus)
- Skin rash
- Hives (urticaria)
- Injection site pain and reactions
- Weakness (asthenia)
- Increased heart rate (tachycardia)
Rare
- Allergic reactions (throat tightness, difficulty breathing, chest discomfort, swelling, low blood pressure)
- Anxiety
- Seizures, abnormal coordination, impaired mental function
- Increased tear production
- Tinnitus (ringing in the ears)
- Changes in heart rhythm
- Throat spasm, shortness of breath, runny nose, cough, wheezing
- Abdominal pain, tongue swelling, mouth itching, gum inflammation, diarrhea
- Facial swelling
- Muscle stiffness
- Chest pain, fever
Not Known
- Coma
- Loss of consciousness
- Vasovagal reaction (fainting with nausea, dizziness, sweating, slow pulse)
- Cardiac arrest
- Respiratory arrest, pulmonary edema
- Angioedema (severe swelling of face, tongue, or throat)
- Renal failure
- Nephrogenic systemic fibrosis (skin hardening, may affect soft tissues and internal organs)
If you experience difficulty breathing, severe swelling of the face, lips, tongue, or throat, severe dizziness, or loss of consciousness after receiving ProHance, alert the medical staff immediately. These may be signs of a severe allergic reaction (anaphylaxis) requiring emergency treatment.
Nephrogenic systemic fibrosis (NSF): Isolated cases of NSF have been reported in association with ProHance use. NSF is a serious condition that causes progressive hardening and thickening of the skin and may also affect soft tissues and internal organs. Most reported cases occurred in patients with severe renal impairment who had also received other gadolinium-containing contrast agents. The risk of NSF with macrocyclic agents like ProHance is considered very low compared to linear gadolinium agents.
Children and adolescents: The side effects observed in pediatric patients who have received ProHance are similar in nature and frequency to those seen in adults. No additional or unique pediatric safety concerns have been identified in clinical studies.
It is important to report suspected side effects after a medicine has been authorized. This helps to continuously monitor the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority.
How Should You Store ProHance?
As a hospital-administered medication, ProHance storage is primarily the responsibility of healthcare facilities and pharmacies. However, understanding proper storage conditions ensures the integrity and safety of the product.
ProHance should be stored in its original outer carton to protect it from light. It is a light-sensitive solution, and prolonged exposure to light may affect the stability of the gadoteridol chelate complex. The product should be kept out of the sight and reach of children at all times.
Check the expiry date (marked as "EXP" on the label and outer packaging) before use. The expiry date refers to the last day of the stated month. Do not use ProHance after this date, as the manufacturer can no longer guarantee the quality and efficacy of the product.
If ProHance vials or pre-filled syringes are accidentally frozen, the product should be thawed slowly at room temperature (approximately 60 to 90 minutes) until it returns to a clear, colorless or slightly yellowish appearance. The solution should be visually inspected before use to ensure that all particulate matter has dissolved and that there is no damage to the vial or stopper.
Unused medicine should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. These measures help protect the environment and prevent accidental exposure.
What Does ProHance Contain?
Understanding the full composition of ProHance is important for identifying potential allergens and understanding the pharmaceutical formulation. The product is a sterile, clear, colorless to slightly yellowish solution designed for intravenous injection.
Active substance: Gadoteridol. Each milliliter of solution contains 279.3 mg of gadoteridol, equivalent to 0.5 mmol gadolinium per mL. Gadoteridol is a non-ionic, macrocyclic gadolinium chelate that provides paramagnetic contrast enhancement during MRI examinations.
Other ingredients (excipients):
- Calteridol calcium: A stabilizing agent that helps maintain the integrity of the gadolinium chelate complex and prevents transmetallation (release of gadolinium from the chelate).
- Tromethamine (trometamol): A buffering agent that maintains the solution at an appropriate pH for intravenous administration.
- Hydrochloric acid or sodium hydroxide: Used for pH adjustment to ensure the solution is within the optimal pH range.
- Water for injections: The solvent used to prepare the sterile solution.
Available Packaging
Vials: Available in volumes of 5, 10, 15, 20, or 50 mL. Pack sizes include configurations of 1, 5, or 10 vials, depending on the volume. The vials are designed for single use, and any unused contents should be discarded.
Pre-filled syringes: Available in volumes of 10, 15, or 17 mL, supplied as single-syringe packs. Pre-filled syringes offer the convenience of ready-to-use administration and reduce the risk of contamination during preparation.
Not all pack sizes may be available in every country. The marketing authorization holder is Bracco International B.V., based in Amsterdam, Netherlands.
Frequently Asked Questions About ProHance
Medical References and Sources
This article is based on current medical research, regulatory documents, and international guidelines. All claims are supported by evidence from peer-reviewed and authoritative sources.
- European Medicines Agency (EMA). "ProHance — Summary of Product Characteristics." EMA product information database. Official European regulatory prescribing information for ProHance.
- U.S. Food and Drug Administration (FDA). "ProHance (Gadoteridol) Injection — Prescribing Information." FDA-approved prescribing information including indications, dosage, contraindications, and adverse reactions.
- American College of Radiology (ACR). "ACR Manual on Contrast Media, Version 2024." ACR Committee on Drugs and Contrast Media. Comprehensive guidelines on the safe use of contrast agents, including gadolinium-based agents and NSF risk assessment.
- European Society of Urogenital Radiology (ESUR). "ESUR Guidelines on Contrast Agents, Version 10.0 (2018)." European guidelines covering GBCA safety, including recommendations for patients with renal impairment.
- Kanal E, et al. (2015). "Residual or retained gadolinium: practical implications for radiologists and our patients." Radiology. 275(3):630-634. Key publication on gadolinium deposition and implications for macrocyclic vs. linear agent selection.
- Kanda T, et al. (2015). "High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images." Radiology. 274(1):171-179. Landmark study identifying gadolinium deposition in brain structures following repeated GBCA administration.
- World Health Organization (WHO). "WHO Model List of Essential Medicines — Diagnostic Agents." 23rd List (2023). WHO classification of essential diagnostic agents including MRI contrast media.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Drug safety and efficacy data are based on regulatory review documents and published clinical trial results.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in radiology, pharmacology, internal medicine, and nephrology.